Moving towards dose individualization of tyrosine kinase inhibitors.

[1]  Jian-yong Li,et al.  Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia , 2011, Medical oncology.

[2]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[3]  H. Guchelaar,et al.  Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib. , 2010 .

[4]  J. Schellens,et al.  Pharmacogenetic factors predicting the need for a higher dose of imatinib. , 2010 .

[5]  T. Mukohara,et al.  Effect of axitinib (AG‐013736) on fatigue, thyroid‐stimulating hormone, and biomarkers: A phase I study in Japanese patients , 2010, Cancer Science.

[6]  Tae Won Kim,et al.  Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Burris,et al.  Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumors , 2010, Cancer.

[8]  H. Kantarjian,et al.  Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib , 2010, Clinical pharmacology and therapeutics.

[9]  E. Wiemer,et al.  A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan , 2010, Clinical Cancer Research.

[10]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[11]  J. Fletcher,et al.  Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment , 2009, Clinical Cancer Research.

[12]  Xin Huang,et al.  Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure , 2009, Clinical Cancer Research.

[13]  H. Guchelaar,et al.  Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Demetri,et al.  Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Merkle,et al.  Phase I Trial of Pazopanib in Patients with Advanced Cancer , 2009, Clinical Cancer Research.

[16]  J. H. Beijnen,et al.  Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor , 2009, Cancer Chemotherapy and Pharmacology.

[17]  Dongwoo Kang,et al.  A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients , 2009, Clinical Cancer Research.

[18]  A. Stead,et al.  Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Kumar,et al.  Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders , 2009, European Journal of Clinical Pharmacology.

[20]  L. Johnson.  Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.

[21]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[22]  V. Lorusso,et al.  How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Liwu Fu,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914)) , 2008 .

[24]  B. Geoerger,et al.  Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults , 2008, Clinical Cancer Research.

[25]  M. Pirmohamed,et al.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.

[26]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[27]  Gregory Karczmar,et al.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Gurney,et al.  Dose calculation of anticancer drugs , 2008, Expert Opinion on Drug Metabolism & Toxicology.

[29]  Richard Pazdur,et al.  Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.

[30]  Susan Goodin,et al.  Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. , 2008, Clinical Therapeutics.

[31]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[32]  P. Bycott,et al.  Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study , 2008 .

[33]  H. Wildiers,et al.  Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) , 2008 .

[34]  G. Demetri,et al.  Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) , 2008 .

[35]  S. Baker,et al.  Interaction of Imatinib with Human Organic Ion Carriers , 2008, Clinical Cancer Research.

[36]  Tillmann Krahnke,et al.  Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.

[37]  H. Lane,et al.  Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Kelly A. Harmon,et al.  The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions , 2008, Drug Metabolism and Disposition.

[39]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Liddle,et al.  Transporter pumps and imatinib: A cause of pharmacokinetic resistance? , 2008, Cancer biology & therapy.

[41]  F. Lee,et al.  Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL , 2008, Cancer Chemotherapy and Pharmacology.

[42]  F. Kabbinavar,et al.  A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period , 2008, Cancer Chemotherapy and Pharmacology.

[43]  Pingfu Fu,et al.  Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Sonpavde,et al.  Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma , 2008, Expert opinion on investigational drugs.

[45]  R. Pazdur,et al.  Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.

[46]  M. Steinberg.  Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. , 2007, Clinical therapeutics.

[47]  E. Rowinsky,et al.  Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Ratain,et al.  The value meal: how to save $1,700 per month or more on lapatinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  D. Richel,et al.  Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors , 2007, Clinical Cancer Research.

[50]  E. Hanrahan,et al.  Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer , 2007, Clinical Cancer Research.

[51]  K. Owzar,et al.  Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Leggas,et al.  Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. , 2007, Clinical therapeutics.

[53]  G. Mann,et al.  Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype , 2007, Clinical pharmacology and therapeutics.

[54]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[55]  S. Srinivas,et al.  A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC) , 2007 .

[56]  P. Adamson,et al.  Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group , 2007 .

[57]  G. Pond,et al.  Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  H. Izzedine,et al.  Hypertension as a predictive factor of Sunitinib activity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  Nicholas Moore,et al.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.

[60]  Y. Wang,et al.  Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.

[61]  S. Bates,et al.  Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.

[62]  Y. Cho,et al.  Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance , 2007, Leukemia & lymphoma.

[63]  M. Hidalgo,et al.  Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.

[64]  Manuel Hidalgo,et al.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.

[65]  R. Perez-soler.  Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. , 2006, Clinical lung cancer.

[66]  J. Verweij,et al.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.

[67]  Zheng Yang,et al.  Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure , 2006, Clinical Cancer Research.

[68]  A. Rottmann,et al.  Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients , 2006, Drug Metabolism and Disposition.

[69]  J. Blay,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors , 2006, Clinical Cancer Research.

[70]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[71]  R. Bruno,et al.  Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer , 2006, Clinical pharmacology and therapeutics.

[72]  Nicolas Widmer,et al.  Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. , 2006, British journal of clinical pharmacology.

[73]  L. Kanz,et al.  The HIV protease inhibitor ritonavir and the proteasome inhibitor bortezomib induce synergistic cytotoxicity on soft tissue sarcoma cells in vitro. , 2006, Journal of Clinical Oncology.

[74]  H. Kantarjian,et al.  High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[76]  M. Radtke,et al.  Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.

[77]  H. Gurney.  Developing a new framework for dose calculation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  G. Pond,et al.  Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer , 2006, British Journal of Cancer.

[79]  John Smeraglia,et al.  Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects , 2006, Anti-cancer drugs.

[80]  C. Prakash,et al.  METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.

[81]  M. Hidalgo,et al.  Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients , 2006, Investigational New Drugs.

[82]  V. Fischer,et al.  Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects. , 2005 .

[83]  A. Oza,et al.  Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  M. van Glabbeke,et al.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Jeffrey W. Clark,et al.  Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.

[88]  H. Hurwitz,et al.  Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  P. Ghahramani,et al.  The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects , 2005 .

[91]  T. Roskams,et al.  Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC) , 2005 .

[92]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[93]  J. Verweij,et al.  Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group , 2005, Cancer Chemotherapy and Pharmacology.

[94]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  H. Döhner,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[96]  G. Mann,et al.  Hepatic Technetium Tc 99m–labeled Sestamibi Elimination Rate and ABCB1 (MDR1) Genotype as Indicators of ABCB1 (P–glycoprotein) Activity in Patients with Cancer , 2005, Clinical pharmacology and therapeutics.

[97]  M. Bernstein,et al.  Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.

[98]  A. Tolcher,et al.  Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule , 2004, Clinical Cancer Research.

[99]  M. Egorin,et al.  Effect of St John's Wort on imatinib mesylate pharmacokinetics , 2004, Clinical pharmacology and therapeutics.

[100]  K. Nooter,et al.  Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib , 2004, Cell cycle.

[101]  Y. Daali,et al.  A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. , 2004, Journal of pharmaceutical and biomedical analysis.

[102]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[103]  S. Steinberg,et al.  Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  A. Hochhaus,et al.  Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance , 2004, Leukemia.

[105]  R. Smith,et al.  The effect of food on and the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  R. Capdeville,et al.  Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects , 2004, Cancer Chemotherapy and Pharmacology.

[107]  A. Telenti,et al.  Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity , 2004, European Journal of Clinical Pharmacology.

[108]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  M. Ranson,et al.  Gefitinib, a novel, orally administered agent for the treatment of cancer , 2004, Journal of clinical pharmacy and therapeutics.

[110]  B. Dörken,et al.  Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 , 2004, Cancer Chemotherapy and Pharmacology.

[111]  A. Racine‐Poon,et al.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  M. Ben-Am,et al.  Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion , 2004, Journal of clinical pharmacology.

[113]  E. Schuetz.  Lessons from the CYP3A4 promoter. , 2004, Molecular pharmacology.

[114]  R. Capdeville,et al.  Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects , 2004, Cancer Chemotherapy and Pharmacology.

[115]  R. Capdeville,et al.  Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules , 2004, Cancer Chemotherapy and Pharmacology.

[116]  H. Lane,et al.  Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.

[117]  P. Paschka,et al.  Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C , 2003, Leukemia.

[118]  D. Soulières.  Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash. , 2003, Oncology.

[119]  R. Perez-soler.  Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? , 2003, Oncology.

[120]  J. Klein,et al.  Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa , 2003, The Lancet.

[121]  M. Hidalgo,et al.  Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). , 2003, Seminars in oncology.

[122]  S. Clarke,et al.  Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.

[123]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[124]  Wooin Lee,et al.  The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.

[125]  L. Grochow,et al.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.

[126]  A. Harris,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  S. Clarke,et al.  Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response , 2002, British Journal of Cancer.

[129]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[130]  D. Newell.  Getting the right dose in cancer chemotherapy – time to stop using surface area? , 2002, British Journal of Cancer.

[131]  O. S. Nielsen,et al.  Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.

[132]  J. Kovarik,et al.  Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment , 2001, Clinical pharmacology and therapeutics.

[133]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[134]  E. Perucca,et al.  Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants? , 2000, Clinical pharmacokinetics.

[135]  M. Ingelman-Sundberg,et al.  Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. , 1999, Pharmacogenetics.

[136]  M. Ratain,et al.  Oral chemotherapy: rationale and future directions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  G Levy,et al.  Predicting Effective Drug Concentrations for Individual Patients , 1998, Clinical pharmacokinetics.

[138]  K. Kolibaba,et al.  Protein tyrosine kinases and cancer. , 1997, Biochimica et biophysica acta.

[139]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[140]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[142]  G. Deray,et al.  Hypertension and proteinuria: a class-effect of antiangiogenic therapies. , 2009, Anti-cancer drugs.

[143]  B. Lum,et al.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.

[144]  J. Singer,et al.  UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia , 2007, Leukemia.

[145]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  J. Koopmeiners,et al.  Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. , 2006, Lung cancer.

[147]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[148]  A. Stead,et al.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects , 2004, Investigational New Drugs.

[149]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  M. Manns,et al.  Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.

[151]  Erich Querfurth,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[152]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[153]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[154]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.